UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Proceedings of the National Academy of Sciences - PNAS, 2016-10, Vol.113 (41), p.E6145-E6152

2016

Link zum Volltext

Verfügbarkeit prüfen

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Multiple sclerosis, 2022-04, Vol.28 (4), p.608-619

2022

Link zum Volltext

Verfügbarkeit prüfen

Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS

Multiple sclerosis, 2019-02, Vol.25 (2), p.217-223

2019

Link zum Volltext

Verfügbarkeit prüfen

Causes of death among commercially insured multiple sclerosis patients in the United States

PloS one, 2014-08, Vol.9 (8), p.e105207-e105207

2014

Link zum Volltext

Verfügbarkeit prüfen

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Genome medicine, 2017-05, Vol.9 (1), p.50-50, Article 50

2017

Link zum Volltext

Verfügbarkeit prüfen

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

PloS one, 2011-11, Vol.6 (11), p.e22444-e22444

2011

Link zum Volltext

Verfügbarkeit prüfen

Sample Size Estimates for Clinical Trials of Vasospasm in Subarachnoid Hemorrhage

Stroke (1970), 2009-07, Vol.40 (7), p.2362-2367

2009

Link zum Volltext

Verfügbarkeit prüfen

Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy

Clinical therapeutics, 2011-07, Vol.33 (7), p.914-925

2011

Link zum Volltext

Verfügbarkeit prüfen

An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration

The American heart journal, 2008-07, Vol.156 (1), p.106-111

2008

Link zum Volltext

Verfügbarkeit prüfen

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial

Clinical pharmacology and therapeutics, 2021-05, Vol.109 (5), p.1224-1231

2021

Link zum Volltext

Verfügbarkeit prüfen

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial

JAMA neurology, 2020-05, Vol.77 (5), p.613

2020

Link zum Volltext

Verfügbarkeit prüfen

Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis

Clinical & experimental neuroimmunology, 2017-05, Vol.8 (2), p.129-137

2017

Link zum Volltext

Verfügbarkeit prüfen

Mortality in patients with multiple sclerosis

Neurology, 2013-07, Vol.81 (2), p.184

2013

Link zum Volltext

Verfügbarkeit prüfen

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke

Critical care medicine, 2004, Vol.32 (1), p.241-245

2004

Link zum Volltext

Verfügbarkeit prüfen

The dose of aspirin for the prevention of cardiovascular and cerebrovascular events

Current medical research and opinion, 2006-07, Vol.22 (7), p.1239-1248

2006

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

Clinical therapeutics, 2012-05, Vol.34 (5), p.1132-1144

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam

Experimental neurology, 2023-02, Vol.360, p.114286-114286, Article 114286

2023

Link zum Volltext

Verfügbarkeit prüfen

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

Acta neurologica Scandinavica, 2020-12, Vol.142 (6), p.531-540

2020

Link zum Volltext

Verfügbarkeit prüfen

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial

JAMA neurology, 2021-03, Vol.78 (3), p.285

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis

Expert opinion on drug safety, 2017-02, Vol.16 (2), p.247-255

2017

Link zum Volltext

Verfügbarkeit prüfen

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

Epilepsia (Copenhagen), 2021-05, Vol.62 (5), p.1130-1140

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research

Progress in neurobiology, 2017-05, Vol.152, p.114-130

2017

Link zum Volltext

Verfügbarkeit prüfen

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta -1b trial in multiple sclerosis

Journal of neurology, neurosurgery and psychiatry, 2012-03, Vol.83 (3), p.282-287

2012

Link zum Volltext

Verfügbarkeit prüfen

Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense “black holes”: a post hoc magnetic resonance imaging analysis

Journal of neurology, 2015-03, Vol.262 (3), p.648-653

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS

Causes of death among commercially insured multiple sclerosis patients in the United States

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

Sample Size Estimates for Clinical Trials of Vasospasm in Subarachnoid Hemorrhage

Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy

An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial

Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis

Mortality in patients with multiple sclerosis

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke

The dose of aspirin for the prevention of cardiovascular and cerebrovascular events

Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial

Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta -1b trial in multiple sclerosis

Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense “black holes”: a post hoc magnetic resonance imaging analysis

Suchergebnisse filtern